MedPath

Impact of the Use of CRP on the Prescription of Antibiotics in General Practitioners

Not Applicable
Completed
Conditions
Respiratory Infection
Respiratory Infections in Children
Registration Number
NCT03540706
Lead Sponsor
Centre Hospitalier Intercommunal Creteil
Brief Summary

Respiratory infections, including episodes of coughing with fever, are the main cause of outpatient antibiotic prescription, while a minority of them are linked to bacterial infections requiring antibiotic. These prescriptions are often performed by general practitioners. These unnecessary antibiotic contribute to increased bacterial resistance, side effects and unnecessary costs. Campaigns for the correct prescription of antibiotics have had a real but partial or transient success.

C-reactive protein micro-method (POCT-CRP) could help to differentiate between viral and bacterial infections and thus contribute to the proper use of antibiotics. The decrease in prescription of antibiotics is likely to have an even stronger positive impact in countries like France, where prescription is high.

The objective of this study is to evaluate the use of POCT-CRP in the general practitioner's office in case of suspected respiratory infection.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
406
Inclusion Criteria
  • Age ≥ 3 years
  • Clinical suspicion of respiratory infection defined by the presence of at least one respiratory sign among, cough, dyspnea, chest pain and auscultatory abnormality and at least one general sign among fever, sweat, headache, myalgia, impairment of general condition
  • Affiliated to a social health insurance
  • Signed consent
Exclusion Criteria
  • Duration of symptoms < 24 hours
  • Hospitalization or emergency assessment decision decided from the outset
  • Signs of severity before the realization of POCT-CRP
  • Patient previously included in the study for the same episode
  • Antibiotic therapy within 7 days
  • Chronic cough (more than 3 weeks)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Frequency of antibiotic therapy prescribed10 days

with and without POCT-CRP

Secondary Outcome Measures
NameTimeMethod
Frequency of complementary exam10 days

with and without POCT-CRP

type of complementary exam10 days

with and without POCT-CRP

Proportion of number of patients with delayed antibiotic therapy10 days

with and without POCT-CRP

COVID-19 positive patients1 day

Number of COVID-19 positive patients by diagnostic method (From October 2020)

Frequency of antibiotic therapy prescribed in patients aged from 18 to 64 years old10 days

with and without POCT-CRP

number of prescription following the recommended algorythms10 days

Adequacy between the proposed decision algorithm according to the C-reactive protein assay and the antibiotic prescription

Frequency of antibiotic therapy prescribed in patients aged from 3 to 17 years old10 days

with and without POCT-CRP

Frequency of antibiotic therapy prescribed in patients older than 65 years old10 days

with and without POCT-CRP

Proportion of number of patients referred to emergency10 days

with and without POCT-CRP

Concordance between the prescription proposed by the decision algorithm as a function of the micro-CRP and the prescription realized: kappa coefficient10 days

The assessment of the utility of the POCT procedure

Type of antibiotic prescribed10 days

Trial Locations

Locations (14)

22 rue de Silly

🇫🇷

Boulogne, France

18 rue Sainte Bathilde

🇫🇷

Chelles, France

25 avenue des frères Lumière

🇫🇷

Cormeilles-en-Parisis, France

8 Rue Saint-Exupéry

🇫🇷

Meudon La Forêt, France

258 Bis Rue de Paris

🇫🇷

Montreuil, France

61bis Boulevard de Charonne

🇫🇷

Paris, France

25 Rue de Fécamp

🇫🇷

Paris, France

237 Rue de la Croix Nivert,

🇫🇷

Paris, France

1 Rue Colette Magny

🇫🇷

Paris, France

391 Rue des Pyrénées

🇫🇷

Paris, France

Scroll for more (4 remaining)
22 rue de Silly
🇫🇷Boulogne, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.